Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
idasanutlin + venetoclax
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The **idasanutlin + venetoclax** combination is an investigational oral therapy for acute myeloid leukemia (AML), particularly in relapsed/refractory or secondary cases not eligible for intensive chemotherapy. **Idasanutlin** is a selective small molecule antagonist of **MDM2**, inhibiting the MDM2-p53 interaction and thereby reactivating p53 tumor suppressor activity, leading to cell cycle arrest and apoptosis in p53 wild-type cells. **Venetoclax** is a BCL-2 inhibitor (BH3 mimetic), promoting apoptosis in cells dependent on BCL-2 for survival. Preclinical and early clinical studies show that this combination acts synergistically, accelerating induction of apoptosis, overcoming the cell-cycle dependency of idasanutlin, and enhancing anti-leukemic efficacy compared to single agents. Clinical trials have demonstrated promising composite complete remission rates and manageable safety, supporting further clinical development in AML[1][2][3][5].
- Brand names
- none identified for the combination
- Other names
- RG7388 + venetoclaxven-idasa
02
Targets
BCL-2 (BCL-2 family)MDM2 (Mouse double minute 2 homolog)
Beyond the preview
Go deeper on idasanutlin + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on idasanutlin + venetoclax.